XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Inclusion Criteria: * Age ≥18 years, male and female, * Confirmed as CD19-positive B cell lymphoma/leukemia by immunohistochemistry or flow cytometry * No effective treatment * Patients must have a measurable or evaluable disease at the time of enrollment. * Adequate organ system function including: * ALT/AST \< 3 upper limit of normal; Total Bilirubin \< 2.5 upper limit of normal * Creatinine \< 2 upper limit of normal * Oxygen saturation ≥ 95% * Left ventricular ejection fraction ≥ 40% * Number of neutrophil ≥ 0.75×10\^9/L, number of platelet ≥ 50×10\^9/L * At least 4 weeks from receiving previous treatment (radiotherapy, chemotherapy, monoclonal antibody therapy or other treatments) * No contraindications of peripheral blood apheresis * Female subjects in childbearing age, their serum or urine pregnancy test must be negative. All patients must agree to take effective contraceptive measures during the trial measures * ECOG score 0-2, expected survival ≥ 12 weeks Exclusion Criteria: * Women who are pregnant or lactating. Patients have breeding intent in 12 months or cannot take effective contraceptive measures during the trial measures * Uncontrollable active infection within four week. Prophylactic antibiotic, antiviral and antifungal treatment is permissible. Active hepatitis B or hepatitis C virus infection, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons * Subjects with any autoimmune disease or any immune deficiency disease * Have a history of allergy to antibodies or cellular products * Participated in any other clinical trial within four weeks * Used of systemic steroids within four weeks (using inhaled steroids or ≤ 20mg/d prednison are exceptions) * Have mental diseases * Have history of drug addiction * The investigators believe that any increase in the risk of the subject or interference with the results of the trial